Nutritional and Genetic Markers of Breast Cancer

乳腺癌的营养和遗传标志物

基本信息

  • 批准号:
    7250218
  • 负责人:
  • 金额:
    $ 28.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-09-28 至 2009-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We propose to conduct a prospective study of nutritional biomarkers and corresponding gene variants involved in one-carbon metabolism-and their interactive effects-on breast cancer risk in the Women's Health Study (WHS). A total of 1,100 incident cases of breast cancer will be identified and confirmed among 28,345 participants with archived baseline blood specimens. We will assay five nutritional biomarkers (i.e. plasma folate, vitamins B6 and B12, cysteine, and homocysteine). Applying state-of-the-art genotyping technology and statistical methods, we will evaluate functional variants and determine the structure of haplotypes in twelve relevant candidate genes. These genes will include glutamatecysteine ligase (GCLC [catalytic subunit] and GCLM[regulatory subunit]), folate-metabolizing genes (reduced folate carrier-1 [RFC], 5,10-methylene-tetrahydrofolate reductase [MTHFR], methionine synthase [MTR], methionine synthase reductase [MTRR], serine hydroxymethyltransferase [SHMT1], and thymidylate synthase [TYMS]), catechol-O-methyltransferase (COMT), and DNA repair genes (X-ray repair cross complementing [XRCC]-1, 2, and 3). There are at least three interrelated pathways by which these markers may be associated with breast cancer risk. First, folate and vitamin B12 affect methyl group availability and may thus prevent abnormal DNA methylation. Second, folate and vitamins B6 and B12 influence DNA synthesis and repair. Third, cysteine is the key amino acid in the synthesis of glutathione (GSH), an important intracellular antioxidant and detoxifying agent. GCLC and GCLM genes encode a rate-limiting enzyme for GSH biosynthesis from cysteine. Available data also suggest that folate interacts with alcohol intake to affect breast cancer risk. However, no published data have evaluated whether GCLC, GCLM, RFC, MTR, MTRR, SHMT1, and TYMS polymorphisms affect breast cancer risk. Findings from this study will help provide a basis for public health recommendations regarding optimal levels of folate and B vitamin intakes, suggest new prevention strategies, and identify high-risk individuals. Several unique features of the WHS, including its prospective design, large sample size, long duration, high follow-up rates, availability of stored blood specimens, comprehensive covariate information, and cost efficiency, make this cohort a valuable and exceptional resource for the etiologic investigation of breast cancer.
描述(由申请人提供):我们建议在妇女健康研究(WHS)中进行一项前瞻性研究,研究涉及一碳代谢的营养生物标志物和相应的基因变异及其相互作用对乳腺癌风险的影响。在28,345名具有存档基线血液标本的参与者中,将确定和确认总共1,100例乳腺癌病例。我们将检测五种营养生物标志物(即血浆叶酸、维生素B6和B12、半胱氨酸和同型半胱氨酸)。应用最先进的基因分型技术和统计学方法,我们将评估功能变体,并确定12个相关候选基因的单倍型结构。这些基因将包括半胱氨酸连接酶(GCLC [催化亚基]和GCLM[调节亚基]),叶酸代谢基因(还原叶酸载体-1 [RFC]、5,10-亚甲基-四氢叶酸还原酶[MTHFR]、甲硫氨酸合成酶[MTR]、甲硫氨酸合成酶还原酶[MTRR]、丝氨酸羟甲基转移酶[SHMT 1]和胸苷酸合成酶[TYMS])、儿茶酚-O-甲基转移酶(COMT),和DNA修复基因(X射线修复交叉互补[XRCC]-1,2和3)。至少有三种相互关联的途径,这些标志物可能与乳腺癌风险相关。首先,叶酸和维生素B12影响甲基的可用性,从而可以防止异常的DNA甲基化。其次,叶酸和维生素B6和B12影响DNA的合成和修复。第三,半胱氨酸是合成谷胱甘肽(GSH)的关键氨基酸,谷胱甘肽是一种重要的细胞内抗氧化剂和解毒剂。GCLC和GCLM基因编码半胱氨酸生物合成GSH的限速酶。现有数据还表明,叶酸与酒精摄入量相互作用,影响乳腺癌的风险。然而,没有发表的数据评估GCLC,GCLM,RFC,MTR,MTRR,SHMT 1和TYMS多态性是否影响乳腺癌的风险。这项研究的结果将有助于为公众健康提供有关叶酸和B族维生素摄入量最佳水平的建议,提出新的预防策略,并确定高危人群。WHS的几个独特的特点,包括其前瞻性设计,大样本量,持续时间长,高随访率,储存的血液标本的可用性,全面的协变量信息,和成本效益,使这个队列的乳腺癌病因调查的宝贵和特殊的资源。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHUMIN ZHANG其他文献

SHUMIN ZHANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHUMIN ZHANG', 18)}}的其他基金

Estrogen and Progesterone-related Gene Variants and Colorectal Cancer Risk
雌激素和孕激素相关基因变异与结直肠癌风险
  • 批准号:
    7136486
  • 财政年份:
    2006
  • 资助金额:
    $ 28.38万
  • 项目类别:
Estrogen and Progesterone-related Gene Variants and Colorectal Cancer Risk
雌激素和孕激素相关基因变异与结直肠癌风险
  • 批准号:
    7275969
  • 财政年份:
    2006
  • 资助金额:
    $ 28.38万
  • 项目类别:
Estrogen and Progesterone-related Gene Variants and Colorectal Cancer Risk
雌激素和孕激素相关基因变异与结直肠癌风险
  • 批准号:
    7666841
  • 财政年份:
    2006
  • 资助金额:
    $ 28.38万
  • 项目类别:
Estrogen and Progesterone-related Gene Variants and Colorectal Cancer Risk
雌激素和孕激素相关基因变异与结直肠癌风险
  • 批准号:
    7488912
  • 财政年份:
    2006
  • 资助金额:
    $ 28.38万
  • 项目类别:
Nutritional and Genetic Markers of Breast Cancer
乳腺癌的营养和遗传标志物
  • 批准号:
    7126513
  • 财政年份:
    2005
  • 资助金额:
    $ 28.38万
  • 项目类别:
Nutritional and Genetic Markers of Breast Cancer
乳腺癌的营养和遗传标志物
  • 批准号:
    6985866
  • 财政年份:
    2005
  • 资助金额:
    $ 28.38万
  • 项目类别:
Nutritional and Genetic Markers of Breast Cancer
乳腺癌的营养和遗传标志物
  • 批准号:
    7463655
  • 财政年份:
    2005
  • 资助金额:
    $ 28.38万
  • 项目类别:
Diet, Hormone Replacement Therapy and Breast Cancer
饮食、激素替代疗法和乳腺癌
  • 批准号:
    7114382
  • 财政年份:
    2003
  • 资助金额:
    $ 28.38万
  • 项目类别:
Diet, Hormone Replacement Therapy and Breast Cancer
饮食、激素替代疗法和乳腺癌
  • 批准号:
    6790035
  • 财政年份:
    2003
  • 资助金额:
    $ 28.38万
  • 项目类别:
Diet, Hormone Replacement Therapy and Breast Cancer
饮食、激素替代疗法和乳腺癌
  • 批准号:
    6611980
  • 财政年份:
    2003
  • 资助金额:
    $ 28.38万
  • 项目类别:

相似海外基金

Development of PMP22 siRNA Conjugates for Treatment of Charcot-Marie-Tooth Disease Type 1A
开发用于治疗 1A 型腓骨肌萎缩症的 PMP22 siRNA 缀合物
  • 批准号:
    10158135
  • 财政年份:
    2020
  • 资助金额:
    $ 28.38万
  • 项目类别:
Genomic basis of phenotypic variability of complex disorders
复杂疾病表型变异的基因组基础
  • 批准号:
    9220180
  • 财政年份:
    2017
  • 资助金额:
    $ 28.38万
  • 项目类别:
Genomic basis of phenotypic variability of complex disorders
复杂疾病表型变异的基因组基础
  • 批准号:
    10618346
  • 财政年份:
    2017
  • 资助金额:
    $ 28.38万
  • 项目类别:
Genomic basis of phenotypic variability of complex disorders
复杂疾病表型变异的基因组基础
  • 批准号:
    10090479
  • 财政年份:
    2017
  • 资助金额:
    $ 28.38万
  • 项目类别:
Genomic basis of phenotypic variability of complex disorders
复杂疾病表型变异的基因组基础
  • 批准号:
    10467208
  • 财政年份:
    2017
  • 资助金额:
    $ 28.38万
  • 项目类别:
Mechanisms of Repetitive Element Mediated Genomic Rearrangements
重复元件介导的基因组重排的机制
  • 批准号:
    9620141
  • 财政年份:
    2016
  • 资助金额:
    $ 28.38万
  • 项目类别:
Mechanisms of Repetitive Element Mediated Genomic Rearrangements
重复元件介导的基因组重排的机制
  • 批准号:
    9162833
  • 财政年份:
    2016
  • 资助金额:
    $ 28.38万
  • 项目类别:
Robust trans-synaptic labeling technologies for cell type-specific quantitation of synaptic connectivity
强大的跨突触标记技术,用于突触连接的细胞类型特异性定量
  • 批准号:
    8935699
  • 财政年份:
    2015
  • 资助金额:
    $ 28.38万
  • 项目类别:
MUTATIONAL SIGNATURE OF CHROMOSOMAL REARRANGEMENT MECHANISMS
染色体重排机制的突变特征
  • 批准号:
    9334277
  • 财政年份:
    2014
  • 资助金额:
    $ 28.38万
  • 项目类别:
MUTATIONAL SIGNATURE(S) OF HUMAN GENOMIC REARRANGEMENT MECHANISMS
人类基因组重排机制的突变特征
  • 批准号:
    10363624
  • 财政年份:
    2014
  • 资助金额:
    $ 28.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了